Yabao Pharmaceutical Co., Inc., a pharmaceutical company in China, announced a second strategic collaboration for the treatment of diabetes with Eli Lilly and Company to co-develop Lilly’s sodium-glucose linked transporter inhibitor (SGLT1) molecule. Lilly’s SGLT1 inhibitor program has completed a Phase I study in Singapore in addition to preclinical development. In July 2014, Lilly and Yabao announced the co-development of Lilly’s glucokinase activator (GKA), LY2608204.

Under the agreement, Yabao receives the rights to develop and commercialize the SGLT1 compound in China while Lilly retains rights in all other markets. The parties will collaborate to determine a strategic development plan for China, and Yabao will initially be responsible to perform and fund all development. Lilly retains future buy-in options for China. Financial terms were not disclosed.

Yabao Pharmaceutical is a lChinese pharmaceutical company with fully-integrated development, manufacturing, and commercialization in China. Yabao is recently pursuing strategic development of innovative pharmaceuticals in addition to Yabao’s well-established business in modern traditional Chinese medicines and chemical-based generic drugs. The company has capabilities in clinical, regulatory, formulation and API production and meets cGMP requirements with facilities approved by the U.S. FDA and European agency.

Source: Yabao Pharmaceutical